RxDoctor Payments Data

Keri Halsema, NP

Adult Health · Aurora, CONPI 1720270101

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (33.5%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Incyte Corporation at 37.7% of the total. Among adult health clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,154in general payments, 2019–2025

Across 85 payments — averaging $201.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$6K
  • Sanofi-aventis U.S. LLC$6K
  • CTI Biopharma Corp.$1K
  • AbbVie$514
  • Johnson & Johnson$439
  • Legend Biotech USA Inc.$379
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$5,74633%
  • Speaking & faculty fees$5,47632%
  • Travel & lodging$3872%
  • Food & beverage$5,29231%
  • Education$2531%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,154 in reported general payments places this provider in the 95th percentile of 430 adult health providers in Colorado.

See all adult health providers in Colorado

Medicare billing

Part B allowed, 2024
$36,562
Medicare patients
166
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban32$38,216
XareltoRivaroxaban20$23,521
Acyclovir104$4,775
ValacyclovirValacyclovir Hcl11$1,067
Levofloxacin23$758
Prochlorperazine Maleate31$480
Fluconazole12$430
Potassium Chloride26$377
Mirtazapine23$316
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim38$309
Triamcinolone Acetonide13$192
Famotidine14$190
Warfarin Sodium19$158
Gabapentin12$151
Allopurinol19$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$439$23,52120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 430 adult health providers in Colorado.

Other adult health in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →